Quote:
Originally Posted by johnt
I can only find the Abstract describing this research:
https://www.iaprd-world-congress.com..._Abstracts.pdf
The conclusions:
"a single time oral administration of Nilotinib may increase brain dopamine levels and metabolism. These results suggest Nilotinib, in a dose dependent manner, may have a symptomatic effect through modulation of brain dopamine levels. Additionally, the significant reduction of oligomeric alpha-synuclein, which is expected to increase in the CSF of PD patients as the disease progresses, suggests that Nilotinib may reduce misfolded alpha-synuclein accumulation and have a longterm disease modifying effect. Importantly, the dose response of oligomeric alpha-synuclein and HVA changes to nilotinib suggests that the dose administered may depend on the stage of disease to potentially halt PD progression."
John
|
Yes, as Jeff replied, this was only presented as an Abstract at the Oral Poster Presentation of the 2018 iaprd. This is a common occurrence to present abstracts and posters of ongoing clinical resesrch to provide updates as data is analysed.